Equities research analysts expect Immune Design Corp. (NASDAQ:IMDZ) to announce earnings per share of ($0.68) for the current quarter, Zacks reports. Two analysts have made estimates for Immune Design Corp.’s earnings, with the highest EPS estimate coming in at ($0.64) and the lowest estimate coming in at ($0.74). Immune Design Corp. reported earnings per share of ($0.60) in the same quarter last year, which would indicate a negative year-over-year growth rate of 13.3%. The business is expected to announce its next earnings results on Wednesday, November 8th.

On average, analysts expect that Immune Design Corp. will report full year earnings of ($2.34) per share for the current fiscal year, with EPS estimates ranging from ($2.54) to ($2.17). For the next financial year, analysts forecast that the business will report earnings of ($2.03) per share, with EPS estimates ranging from ($2.43) to ($1.44). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Immune Design Corp..

Immune Design Corp. (NASDAQ:IMDZ) last posted its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.11. The firm had revenue of $0.73 million for the quarter, compared to analysts’ expectations of $1.50 million. Immune Design Corp. had a negative return on equity of 59.14% and a negative net margin of 324.33%.

A number of equities research analysts have recently weighed in on IMDZ shares. Zacks Investment Research upgraded Immune Design Corp. from a “sell” rating to a “hold” rating in a research report on Thursday, May 18th. Jefferies Group LLC reiterated a “buy” rating and issued a $18.00 price objective (up from $16.00) on shares of Immune Design Corp. in a research report on Friday, May 19th. Cowen and Company reiterated a “buy” rating on shares of Immune Design Corp. in a research report on Tuesday, June 6th. ValuEngine upgraded Immune Design Corp. from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. Finally, BidaskClub lowered Immune Design Corp. from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 5th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Immune Design Corp. has a consensus rating of “Buy” and an average price target of $14.50.

In other news, Director Lewis W. Coleman purchased 12,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 11th. The shares were bought at an average cost of $9.05 per share, for a total transaction of $108,600.00. Following the completion of the transaction, the director now directly owns 40,000 shares of the company’s stock, valued at approximately $362,000. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Lewis W. Coleman purchased 8,000 shares of the company’s stock in a transaction that occurred on Friday, July 7th. The shares were purchased at an average price of $9.27 per share, for a total transaction of $74,160.00. Following the completion of the transaction, the director now directly owns 40,000 shares of the company’s stock, valued at $370,800. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 30,000 shares of company stock worth $272,760. Corporate insiders own 42.90% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC boosted its position in shares of Immune Design Corp. by 170.0% during the first quarter. Renaissance Technologies LLC now owns 111,740 shares of the biotechnology company’s stock valued at $760,000 after purchasing an additional 70,351 shares in the last quarter. Victory Capital Management Inc. boosted its position in shares of Immune Design Corp. by 2.1% during the second quarter. Victory Capital Management Inc. now owns 1,977,564 shares of the biotechnology company’s stock valued at $19,281,000 after purchasing an additional 40,010 shares in the last quarter. Trexquant Investment LP bought a new stake in shares of Immune Design Corp. during the first quarter valued at approximately $183,000. Wells Fargo & Company MN boosted its position in shares of Immune Design Corp. by 46.5% during the first quarter. Wells Fargo & Company MN now owns 148,887 shares of the biotechnology company’s stock valued at $1,012,000 after purchasing an additional 47,266 shares in the last quarter. Finally, TIAA CREF Investment Management LLC boosted its position in shares of Immune Design Corp. by 18.9% during the first quarter. TIAA CREF Investment Management LLC now owns 45,574 shares of the biotechnology company’s stock valued at $310,000 after purchasing an additional 7,236 shares in the last quarter. Institutional investors own 51.46% of the company’s stock.

Immune Design Corp. (NASDAQ IMDZ) opened at 9.30 on Friday. Immune Design Corp. has a 12-month low of $4.50 and a 12-month high of $13.05. The firm’s 50 day moving average price is $9.76 and its 200-day moving average price is $7.87. The company’s market capitalization is $238.26 million.

ILLEGAL ACTIVITY WARNING: This article was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this article on another domain, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this article can be read at https://www.americanbankingnews.com/2017/09/15/zacks-analysts-expect-immune-design-corp-imdz-to-announce-0-68-earnings-per-share.html.

Immune Design Corp. Company Profile

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Get a free copy of the Zacks research report on Immune Design Corp. (IMDZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Immune Design Corp. (NASDAQ:IMDZ)

Receive News & Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related companies with MarketBeat.com's FREE daily email newsletter.